MEDNAX Sees Unusually Large Options Volume (NYSE:MD)

MEDNAX, Inc. (NYSE:MD) was the target of some unusual options trading activity on Tuesday. Investors acquired 776 call options on the company. This represents an increase of 1,392% compared to the average volume of 52 call options.

In related news, Director Roger Md Medel sold 100,000 shares of the business’s stock in a transaction on Thursday, April 1st. The shares were sold at an average price of $25.40, for a total transaction of $2,540,000.00. Following the completion of the transaction, the director now owns 1,318,439 shares in the company, valued at $33,488,350.60. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 3.70% of the stock is currently owned by company insiders.

Several institutional investors have recently modified their holdings of the company. Paces Ferry Wealth Advisors LLC acquired a new stake in MEDNAX in the third quarter valued at about $40,000. Vantage Consulting Group Inc acquired a new position in MEDNAX during the fourth quarter worth $43,000. Skandinaviska Enskilda Banken AB publ acquired a new stake in MEDNAX in the fourth quarter valued at $101,000. First Mercantile Trust Co. purchased a new stake in shares of MEDNAX during the 4th quarter worth $158,000. Finally, MESIROW FINANCIAL INVESTMENT MANAGEMENT Equity & Fixed Income purchased a new position in shares of MEDNAX in the 4th quarter valued at about $162,000. Institutional investors and hedge funds own 95.74% of the company’s stock.

A number of equities analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft upped their price target on MEDNAX from $14.00 to $17.50 and gave the company a “sell” rating in a report on Friday, February 19th. Citigroup reduced their price target on shares of MEDNAX from $24.00 to $22.00 in a research report on Friday, February 19th. Credit Suisse Group dropped their price objective on MEDNAX from $26.00 to $25.00 and set an “outperform” rating on the stock in a report on Thursday, February 25th. Finally, Truist lifted their target price on MEDNAX from $20.00 to $26.00 in a research report on Tuesday, January 5th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company. MEDNAX has an average rating of “Hold” and a consensus target price of $18.77.

Shares of MD stock opened at $24.83 on Thursday. The company has a market capitalization of $2.14 billion, a P/E ratio of -2.87, a price-to-earnings-growth ratio of 1.70 and a beta of 2.09. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 2.16. The business’s 50 day moving average is $25.79 and its two-hundred day moving average is $21.96. MEDNAX has a twelve month low of $10.78 and a twelve month high of $29.25.

MEDNAX (NYSE:MD) last posted its quarterly earnings data on Thursday, February 18th. The company reported $0.25 earnings per share for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.01). The firm had revenue of $416.63 million during the quarter, compared to analysts’ expectations of $456.01 million. MEDNAX had a negative net margin of 26.57% and a positive return on equity of 12.27%. As a group, equities analysts predict that MEDNAX will post 1.08 earnings per share for the current fiscal year.

About MEDNAX

MEDNAX, Inc provides physician services including newborn, anesthesia, maternal-fetal, tele radiology, pediatric cardiology and other pediatric subspecialty care. The firm’s solution include anesthesiology & pain management, prenatal, neonatal, pediatric, radiology, tele radiology, revenue cycle management and perioperative improvement consulting.

See Also: What is the NASDAQ?